Obiltoxaximab

Obiltoxaximab (ETI-204, trade name Anthim) is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1]

Obiltoxaximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetBacillus anthracis anthrax
Clinical data
Trade namesAnthim
Other namesETI-204
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6444H9994N1734O2022S44
Molar mass145.5 kg/mol g·mol−1

This drug was developed by Elusys Therapeutics, Inc.

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.